1. Clinical Case Series Evidence
A published medical case series evaluated the self-administration of fenbendazole in three patients with terminal, stage 4 metastatic cancers:
Stage 4 Metastatic Breast Cancer: An 83-year-old woman presented with widespread metastases in her liver, lungs, spine, and pelvic bones. After declining further conventional chemotherapy and entering hospice care, she began self-administering 222 mg/day of fenbendazole. Over 8 months, her liver enzymes normalized, her tumor marker (CA 27.29) fell from 316 to 36.6, and follow-up PET scans confirmed a complete absence of active tumor metabolic activity. She achieved complete remission and remained recurrence-free nearly 3 years later.
Stage 4 Metastatic Prostate Cancer: A 75-year-old man with extensive bone metastases (spine, pelvis, and humerus) incorporated fenbendazole alongside standard care. His treatment coincided with regression of metastatic lesions and sustained, undetectable PSA levels over 26 months of follow-up.
Stage 4 Metastatic Melanoma: A 63-year-old man with abdominal, muscular, stomach, and spinal metastases achieved complete remission and remained recurrence-free for over 11 months while taking fenbendazole.
2. The Joe Tippens Protocol
The case report highlights the Joe Tippens Protocol, a widely cited self-administration schedule:
Dosing Schedule: Take 222 mg of fenbendazole daily for 3 consecutive days, followed by 4 days off each week.
Dietary Ingestion: Recommends taking fenbendazole with fatty food to enhance drug absorption.
Complementary Supplements: The protocol often includes adjunct supplements, including CBD oil, curcumin, and vitamin D (5,000 IU), to support immune modulation and anti-inflammatory activity.
3. Tolerability & Economic Research Barriers
Safety & Side Effects: Across the evaluated case studies, patients reported no adverse side effects from fenbendazole at the 222 mg dosage level.
Patent & Financial Bottlenecks: Fenbendazole is an inexpensive, generic veterinary drug whose patent expired in the early 1990s. Because generic manufacturing limits potential commercial profitability, pharmaceutical companies face little financial incentive to fund the large-scale, multi-million-dollar randomized controlled clinical trials required for formal oncology approval.
In this video, Dr. John Campbell examines a clinical case series suggesting that fenbendazole, an inexpensive veterinary antiparasitic drug, may possess significant anti-cancer properties. He details the remarkable recoveries of three patients with stage 4 terminal cancers—including breast, prostate, and melanoma—who experienced complete remission or significant regression after self-administering the medication. Campbell notes that because the drug’s patent has expired, pharmaceutical companies have little financial incentive to fund the randomized controlled trials needed for official medical approval. Ultimately, he argues that these “anecdotal” successes should serve as a scientific catalyst for formal research, drawing a historical parallel to how simple observations once led to the discovery of a cure for scurvy.
Important Disclaimer:
Always consult with your licensed healthcare provider before starting any new protocol, medication, or supplement, especially if you have cancer or any serious health condition. Results vary, and mainstream medicine considers these approaches experimental.
We encourage respectful, kind, and supportive discussions.